Clinical Trial - PELOPS

Women who have been diagnosed with Stage 1 - 3 invasive lobular breast cancer (ILC) **who have not yet had surgery to remove their tumor** may be eligible to participate in a two-year clinical trial.

This trial is open to all ER+ and/or PR+ HER2- patients (ductal or lobular), however it is being enriched with lobular breast cancer patients to promote a better understanding of how ILC might respond differently to these therapies.

Go to www.lobularbreastcancer.org/PELOPS to learn more

Name of the Trial:
Palbociclib and Endocrine Therapy for Lobular Breast Cancer Preoperative Study (PELOPS).

Who might qualify? Patients with stage 1 – 3 estrogen and/or progesterone positive, HER2 negative breast cancer, with a minimum 1.5cm tumor, *who have not yet had surgery to remove their tumor* may qualify for the study. This study is open to both premenopausal and postmenopausal patients. Patients with Lobular Breast Cancer are being recruited specifically to form a key cohort for evaluation.

Where can patients enroll? Check ClinicalTrials.gov for the trial locations and contacts.

How to learn more about whether participating in this clinical trial is right for you.

- Read more about the trial at the ClinicalTrials.gov
- Discuss this trial with your doctor. Questions to ask your doctor from the National Institutes of Health can help.

Principle Investigator and Responsible Researcher:

Otto Metzger, MD, Dana-Farber Cancer Institute
Boston, MA ometzger@partners.org 617 632-3352

ClinicalTrials.gov identifier (NCT number): NCT02764541

The Lobular Breast Cancer Alliance shares information about ongoing clinical trials for patients with lobular breast cancer. LBCA does not sponsor or run the clinical trials, and the scientific validity and safety of the trials is the responsibility of the trial investigators. Patients should always discuss their participation in any clinical trial directly with their doctor and learn more by contacting the clinical trial coordinators listed above directly.

Learn more about participating in clinical trials